A model to estimate survival for hepatocellular carcinoma MESH, introduced in 2016, is a score based on the Milan criteria, the presence and type of vascular invasion, C-P score, performance status, and laboratory parameters (AFP and alkaline phosphatase). This evidence concerns the gene AFP and hepatocellular carcinoma.